Related Experiment Video
Updated: Aug 8, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Designing neoantigen cancer vaccines, trials, and outcomes
Nupur Biswas1, Shweta Chakrabarti1, Vijay Padul1
1Rhenix Lifesciences, Hyderabad, India.
Abstract:
Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed in cancer cells. These highly immunogenic antigens may trigger the immune system to combat cancer cells. Improvements in sequencing technology and computational tools have resulted in several clinical trials of neoantigen vaccines on cancer patients. In this review, we have looked into the design of the vaccines which are undergoing several clinical trials. We have discussed the criteria, processes, and challenges associated with the design of neoantigens. We searched different databases to track the ongoing clinical trials and their reported outcomes. We observed, in several trials, the vaccines boost the immune system to combat the cancer cells while maintaining a reasonable margin of safety. Detection of neoantigens has led to the development of several databases. Adjuvants also play a catalytic role in improving the efficacy of the vaccine. Through this review, we can conclude that the efficacy of vaccines can make it a potential treatment across different types of cancers.
Insights
Neoantigen vaccines, targeting mutant cancer proteins, show promise in clinical trials by stimulating the immune system to fight cancer safely. Further research into vaccine design and adjuvants can enhance their efficacy.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Neoantigen vaccines leverage specific epitopes from mutant cancer proteins to elicit an immune response.
- Advances in sequencing and computational biology have enabled the clinical application of neoantigen vaccines.
Purpose of the Study:
- To review the design principles, processes, and challenges in developing neoantigens for cancer vaccines.
- To track and analyze ongoing clinical trials involving neoantigen vaccines and their outcomes.
Main Methods:
- Systematic search of databases for ongoing clinical trials of neoantigen vaccines.
- Review of literature concerning neoantigen identification, vaccine design, and adjuvant roles.
Main Results:
- Clinical trials demonstrate that neoantigen vaccines can effectively boost anti-cancer immunity with a good safety profile.
- Neoantigen detection has spurred the creation of specialized databases.
- Adjuvants significantly contribute to enhancing vaccine efficacy.
Conclusions:
- Neoantigen vaccines represent a promising therapeutic strategy with potential applicability across various cancer types.
- Optimizing vaccine design and incorporating effective adjuvants are key to maximizing therapeutic benefits.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...